Posts

The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.

Vertex Pharmaceuticals announced on Wednesday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the company’s candidate, inaxaplin (VX-147). Inaxaplin was granted the designation for the treatment of APOL1-mediated focal segment glomerulosclerosis (FSGS).

Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company to enhance the patient treatment experience and improve overall outcomes.